Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Bmy    crawled time : 12:15    save search
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
Published: 2021-11-08 (Crawled : 12:15) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: 1.03% H: 0.0% C: 0.0%
lung cancer therapy cancer phase 3 trial nivolumab
Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Presentation at Two Major Scientific Clinical Oncology Conferences in November
Published: 2021-11-03 (Crawled : 12:15) - prnewswire.com
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: -0.46% H: 0.0% C: 0.0%
presentation conference
Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases
Published: 2021-11-03 (Crawled : 12:15) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: -0.46% H: 0.0% C: 0.0%
disease media
Cara Therapeutics Announces CEO Transition
Published: 2021-11-03 (Crawled : 12:15) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: -0.46% H: 0.0% C: 0.0%
CARA | $0.6777 -4.16% -4.34% 220K twitter stocktwits trandingview |
Health Technology
 | | O: -3.38% H: 5.31% C: 4.45%
ceo leo therapeutics
Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
Published: 2021-09-01 (Crawled : 12:15) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: 0.64% H: 0.0% C: -2.2%
AYLA | $0.5036 5.84% -0.7% 0 twitter stocktwits trandingview |
Health Technology
 | | O: -2.6% H: 6.97% C: 6.81%
phase 2 europe ongoing results trial preclinical pre-clinical
EMA Validates Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Published: 2021-08-17 (Crawled : 12:15) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 0.7% C: 0.41%
treatment therapy ema cell carcinoma nivolumab
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
Published: 2021-08-06 (Crawled : 12:15) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: -0.04% H: 0.01% C: -0.39%
SNY | News | $46.66 -2.16% -2.21% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.26% H: 0.0% C: 0.0%
REPL | $6.32 -1.56% -1.58% 630K twitter stocktwits trandingview |
Health Technology
 | | O: 1.76% H: 0.0% C: -11.93%
financial results results
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
Published: 2021-06-29 (Crawled : 12:15) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 0.32% C: -0.2%
satellite treatment rosa europe therapy cancer colorectal cancer approval nivolumab
Blue Spark Technologies Announces Observational Trial Using TempTraq® Wearable Device in CAR T Patient Monitoring
Published: 2021-05-19 (Crawled : 12:15) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: -0.43% H: 0.4% C: 0.35%
device trial car-t
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody ProgramAgenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Published: 2021-05-18 (Crawled : 12:15) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: -0.06% H: 0.58% C: 0.28%
AGEN A | $7.42 14.86% 12.94% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: 29.45% H: 6.64% C: -6.87%
antibody license milestone
Global Active Pharmaceutical Ingredient (API) Market Report 2021-2025: Opportunities in Advancements in API Manufacturing, Growth in the CMOs, & Emergence of Biosimilars Market
Published: 2021-05-10 (Crawled : 12:15) - prnewswire.com
VTRS | News A | $11.55 1.67% 1.65% 7.2M twitter stocktwits trandingview |
Health Technology
 | | O: 6.39% H: 3.3% C: 0.4%
PFE | News 4 | $26.27 -0.19% -0.15% 23M twitter stocktwits trandingview |
Health Technology
 | | O: 0.63% H: 1.13% C: 0.08%
NVS | News | $98.35 1.1% 0.0% 2.2M twitter stocktwits trandingview |
Health Technology
 | | O: 0.05% H: 0.37% C: -0.02%
GSK | News | $40.86 -0.92% -0.15% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.76% H: 0.27% C: -0.28%
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
 | | O: 0.38% H: 0.22% C: -0.72%
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: 0.31% H: 1.01% C: 0.09%
ALB | News | $115.27 0.93% -0.23% 2.2M twitter stocktwits trandingview |
Process Industries
 | | O: 0.41% H: 1.07% C: -2.39%
SNY | News | $46.66 -2.16% -2.21% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 1.54% H: 0.17% C: -0.32%
cmo growth merge biosimilar
Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit
Published: 2021-04-28 (Crawled : 12:15) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: 0.21% H: 0.43% C: -0.11%
life science
Replimune to Host Virtual Investor Event on June 3, 2021
Published: 2021-04-28 (Crawled : 12:15) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: 0.21% H: 0.43% C: -0.11%
REPL | $6.32 -1.56% -1.58% 630K twitter stocktwits trandingview |
Health Technology
 | | O: -0.42% H: 7.88% C: 6.45%
ev
Pyramid Biosciences Announces Leadership Team Expansion
Published: 2021-04-14 (Crawled : 12:15) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: 0.27% H: 0.33% C: 0.09%
expansion bioscience
Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab)
Published: 2021-03-25 (Crawled : 12:15) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M twitter stocktwits trandingview |
Health Technology
 | | O: 1.12% H: 0.0% C: -0.33%
antibody trial nivolumab
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M twitter stocktwits trandingview |
Consumer Services
BOF | $1.99 70.09% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.51 6.03% 40.62% 1.7M twitter stocktwits trandingview |

LICN | $0.941 68.04% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.31 65.5% 39.58% 70M twitter stocktwits trandingview |
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M twitter stocktwits trandingview |
Technology Services
WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services
AIH | $0.45 12.5% 30.92% 320K twitter stocktwits trandingview |
Health Services
MULN | News | $3.78 38.46% 27.78% 13M twitter stocktwits trandingview |
Information
RILY | $29.86 37.48% 27.26% 12M twitter stocktwits trandingview |
Finance
Your saved searches
Save your searches and get alerts when important news are released.